As of 2026-10-07, the EV/EBITDA ratio of Crinetics Pharmaceuticals Inc (CRNX) is -16.38. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CRNX's latest enterprise value is 8,935.61 mil USD. CRNX's TTM EBITDA according to its financial statements is -545.58 mil USD. Dividing these 2 quantities gives us the above CRNX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.0x - 16.1x | 15.4x |
| Forward P/E multiples | 17.0x - 19.1x | 18.0x |
| Fair Price | (87.31) - (82.57) | (85.82) |
| Upside | -202.8% - -197.2% | -201.0% |
| Date | EV/EBITDA |
| 2026-08-31 | -16.38 |
| 2026-08-28 | -16.36 |
| 2026-08-27 | -16.36 |
| 2026-08-26 | -16.36 |
| 2026-08-25 | -16.36 |
| 2026-08-24 | -16.35 |
| 2026-08-21 | -16.33 |
| 2026-08-20 | -16.33 |
| 2026-08-19 | -16.33 |
| 2026-08-18 | -16.33 |
| 2026-08-17 | -16.34 |
| 2026-08-14 | -16.33 |
| 2026-08-13 | -16.28 |
| 2026-08-12 | -16.28 |
| 2026-08-11 | -16.26 |
| 2026-08-10 | -16.22 |
| 2026-08-07 | -16.21 |
| 2026-08-06 | -16.18 |
| 2026-08-05 | -16.19 |
| 2026-08-04 | -16.17 |
| 2026-08-03 | -16.15 |
| 2026-07-31 | -16.10 |
| 2026-07-30 | -16.12 |
| 2026-07-29 | -16.17 |
| 2026-07-28 | -16.17 |
| 2026-07-27 | -16.16 |
| 2026-07-24 | -16.14 |
| 2026-07-23 | -16.13 |
| 2026-07-22 | -16.14 |
| 2026-07-21 | -16.17 |
| 2026-07-20 | -16.17 |
| 2026-07-17 | -16.17 |
| 2026-07-16 | -16.18 |
| 2026-07-15 | -16.17 |
| 2026-07-14 | -16.14 |
| 2026-07-13 | -16.13 |
| 2026-07-10 | -16.11 |